Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Surface protein-focused gene expression analysis identifies prognostic immunophenotypes in newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

ABArwa BohraMayo Clinic in ArizonaSDSurendra DasariMayo Clinic in ArizonaMBMoritz BinderMayo Clinic

Discussion

Loading...

Member takes

Overview

Analysis uncovers prognostic immunophenotypes in multiple myeloma, highlighting gene expression and monoclonal antibodies' roles.

Key Points

  • This research aims to identify prognostic immunophenotypes in multiple myeloma through gene expression analysis.
  • Analyzed RNA-seq and Seq-FISH data from CD138-enriched plasma cells
  • Compared clusters based on clinical characteristics and biomarkers
  • Employed multivariable analysis to determine survival predictors
  • Identified two clusters of myeloma patients: Atypical Cluster 1 and Classical Cluster 2
  • C1 patients showed inferior survival and higher risk, with differences in Beta-2 microglobulin levels
  • Multivariable analysis highlighted C1 status as an independent predictor of outcomes

Cite This Study

Bohra et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d522https://doi.org/10.1182/blood-2025-7477
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden2025
  2. 2Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights2025
  3. 3Multiple myeloma with ≥1% circulating plasma cells in peripheral blood has a poor prognosis2025
  4. 4Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma2025
  5. 5Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights2025